Should I buy or sell Marinus Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRNS shares. View MRNS analyst ratings or view top-rated stocks .

What is Marinus Pharmaceuticals' stock price target for 2024?

7 Wall Street analysts have issued 1-year price objectives for Marinus Pharmaceuticals' stock. Their MRNS share price targets range from $3.00 to $28.00. On average, they expect the company's stock price to reach $16.07 in the next twelve months. This suggests a possible upside of 1,039.8% from the stock's current price. View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts .

How have MRNS shares performed in 2024?

Marinus Pharmaceuticals' stock was trading at $10.87 on January 1st, 2024. Since then, MRNS stock has decreased by 87.0% and is now trading at $1.41. View the best growth stocks for 2024 here .

When is Marinus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MRNS earnings forecast .

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) posted its quarterly earnings results on Tuesday, March, 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.10. The biopharmaceutical company had revenue of $7.19 million for the quarter, compared to the consensus estimate of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative trailing twelve-month return on equity of 269.75%. During the same period in the previous year, the business earned ($0.76) earnings per share.

What ETFs hold Marinus Pharmaceuticals' stock?

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) , iShares Neuroscience and Healthcare ETF (IBRN) and SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

When did Marinus Pharmaceuticals' stock split?

Shares of Marinus Pharmaceuticals reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Marinus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT) , The Gabelli Dividend & Income Trust (GDV) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Capricor Therapeutics (CAPR) , Geron (GERN) , Realty Income (O) , Advanced Micro Devices (AMD) , Novavax (NVAX) and Inovio Pharmaceuticals (INO) .

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free MRNS Stock Alerts

$1.47

+0.06 (+4.26%)

(As of 11:44 AM ET)

Compare

Today's Range: $1.39
▼
$1.55
50-Day Range: $1.20
▼
$10.21
52-Week Range: $1.11
▼
$11.26

Volume: 1.12 million shs
Average Volume: 1.40 million shs
Market Capitalization: $80.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.07

Get Marinus Pharmaceuticals alerts:

Marinus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 1,039.8% Upside
$16.07 Price Target
Short Interest: Bearish
6.32% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.55
Upright™ Environmental Score
News Sentiment: -0.15
Based on 30 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.29) to ($1.43) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.11 out of 5 stars

Medical Sector

135th out of 918 stocks

Pharmaceutical Preparations Industry

47th out of 429 stocks

4.3

Analyst's Opinion

Consensus Rating
Marinus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Marinus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
6.32% of the outstanding shares of Marinus Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Marinus Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Marinus Pharmaceuticals has recently decreased by 2.80%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Marinus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Marinus Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Marinus Pharmaceuticals has received a 60.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Epilepsy medication (N03)", "Clinical research services for Epilepsy or seizures", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Marinus Pharmaceuticals is -1.55.

1.6

News and Social Media Coverage

News Sentiment
Marinus Pharmaceuticals has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 30 news articles for Marinus Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 15 people have searched for MRNS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
76 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 81% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($2.29) to ($1.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Marinus Pharmaceuticals is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Marinus Pharmaceuticals is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Marinus Pharmaceuticals has a P/B Ratio of 4.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

MRNS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MRNS Stock News Headlines

April 19, 2024 | americanbankingnews.com

FY2024 EPS Estimates for Marinus Pharmaceuticals, Inc. Decreased by Cantor Fitzgerald (NASDAQ:MRNS)

April 19, 2024 | americanbankingnews.com

Truist Financial Lowers Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target to $10.00

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 18, 2024 | americanbankingnews.com

Brokers Offer Predictions for Marinus Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:MRNS)

April 17, 2024 | msn.com

Baird Downgrades Marinus Pharmaceuticals (MRNS)

April 17, 2024 | americanbankingnews.com

Marinus Pharmaceuticals (NASDAQ:MRNS) Receives Neutral Rating from Robert W. Baird

April 17, 2024 | americanbankingnews.com

Marinus Pharmaceuticals' (MRNS) Buy Rating Reaffirmed at HC Wainwright

April 16, 2024 | msn.com

RBC Capital Downgrades Marinus Pharmaceuticals (MRNS)

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | americanbankingnews.com

Marinus Pharmaceuticals' (MRNS) Sector Perform Rating Reaffirmed at Royal Bank of Canada

April 15, 2024 | markets.businessinsider.com

Maintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial Health

April 15, 2024 | bizjournals.com

Marinus Pharmaceuticals loses 80% of its market value in one day after setback for new drug candidate

April 15, 2024 | investorplace.com

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

April 15, 2024 | markets.businessinsider.com

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

April 15, 2024 | msn.com

Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?

April 15, 2024 | investorplace.com

Why Are Stocks Up Today?

April 15, 2024 | investorplace.com

Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?

April 15, 2024 | marketwatch.com

Marinus Pharmaceuticals' Trial of Therapy For Persistent Seizures Misses Early Stopping Criteria

April 15, 2024 | businesswire.com

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results

April 11, 2024 | americanbankingnews.com

Cantor Fitzgerald Reaffirms "Overweight" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

April 9, 2024 | msn.com

Marinus Pharmaceuticals Awards Stock Options to New Employees as Inducement

April 5, 2024 | morningstar.com

Marinus Pharmaceuticals Inc MRNS

April 5, 2024 | businesswire.com

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

March 27, 2024 | finance.yahoo.com

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review

March 27, 2024 | businesswire.com

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review

March 20, 2024 | finance.yahoo.com

Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?

March 15, 2024 | ca.finance.yahoo.com

MRNS Jul 2024 16.000 call

See More Headlines

Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MRNS
CUSIP: N/A
CIK: 1267813
Web: www.marinuspharma.com
Phone: (484) 801-4670
Fax: 203-315-0565
Employees: 165
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.07
High Stock Price Target: $28.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +1,039.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-141,400,000.00
Net Margins: -456.31%
Pretax Margin: -461.27%
Return on Equity: -269.75%
Return on Assets: -70.73%

Debt

Debt-to-Equity Ratio: 5.68
Current Ratio: 4.07
Quick Ratio: 4.01

Sales & Book Value

Annual Sales: $30.99 million
Price / Sales: 2.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.31 per share
Price / Book: 4.55

Miscellaneous

Outstanding Shares: 54,930,000
Free Float: 51,932,000
Market Cap: $77.45 million
Optionable: Optionable
Beta: 0.91

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Scott N. Braunstein M.D. (Age 61)
CEO, President & Chairman
Comp: $1.01M
Dr. Alex Aimetti Ph.D.
Chief Scientific Officer
Ms. Sonya Weigle
Senior VP of Investor Relations, Human Resources & Corporate Affairs
Ms. Martha E. Manning Esq. (Age 69)
J. D., Senior VP, General Counsel & Secretary
Molly Cameron
Director of Corporate Communications & Investor Relations
Dr. Kimberly A. McCormick Pharm.D.
Chief Regulatory & Quality Assurance Officer
Mr. Thomas J. Lyons
Chief Business Officer
Mr. David Czekai
Senior Vice President of Chemistry, Manufacturing & Controls
Dr. Mark Paternoster Ph.D.
Senior Vice President of Development
Dr. Dayong Li Ph.D.
Senior Vice President of Biometrics

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRNS shares.
View MRNS analyst ratings or view top-rated stocks.
What is Marinus Pharmaceuticals' stock price target for 2024?: 7 Wall Street analysts have issued 1-year price objectives for Marinus Pharmaceuticals' stock. Their MRNS share price targets range from $3.00 to $28.00. On average, they expect the company's stock price to reach $16.07 in the next twelve months. This suggests a possible upside of 1,039.8% from the stock's current price.
View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts.
How have MRNS shares performed in 2024?: Marinus Pharmaceuticals' stock was trading at $10.87 on January 1st, 2024. Since then, MRNS stock has decreased by 87.0% and is now trading at $1.41.
View the best growth stocks for 2024 here.
When is Marinus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MRNS earnings forecast.
How were Marinus Pharmaceuticals' earnings last quarter?: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) posted its quarterly earnings results on Tuesday, March, 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.10. The biopharmaceutical company had revenue of $7.19 million for the quarter, compared to the consensus estimate of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative trailing twelve-month return on equity of 269.75%. During the same period in the previous year, the business earned ($0.76) earnings per share.

What ETFs hold Marinus Pharmaceuticals' stock?: ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), iShares Neuroscience and Healthcare ETF (IBRN) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
When did Marinus Pharmaceuticals' stock split?: Shares of Marinus Pharmaceuticals reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.
What other stocks do shareholders of Marinus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Realty Income (O), Advanced Micro Devices (AMD), Novavax (NVAX) and Inovio Pharmaceuticals (INO).
How do I buy shares of Marinus Pharmaceuticals?: Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

Marinus Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

MRNS Stock Price History

MRNS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MRNS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™